Progressive Spatial Memory Impairment, Brain Amyloid Deposition And Changes In Serum Amyloid Levels As A Function Of Age In Appswe/Ps1de9 Mice

Lu Fu,Yao Sun,Yongqing Guo,Bin Yu,Haihong Zhang,Jiaxin Wu,Xianghui Yu,Hui Wu,Wei Kong
DOI: https://doi.org/10.2174/1567205015666180709112327
2018-01-01
Current Alzheimer Research
Abstract:Background: Mice co-expressing human amyloid precursor protein with the Swedish mutation (APPswe) and exon-9-deleted presenilin (PS1dE9) has become one of the most widely used mouse models for studying Alzheimer's disease (AD) pathogenesis and preclinical studies of AD therapeutic approaches.Objective: In this study, we systematically investigated cognitive decline, amyloid-beta (A beta) deposition and cerebral or AP serum levels as well as the relationships among these measures in APPswe/PS1dE9 transgenic mice.Method: APPswe/PS1dE9 mice were separated into four equal age cohorts (4, 6, 9, and 12 months). We assessed cognitive capacity, deposited plaques, and the levels of A beta 40/A beta 42 in brain tissue and serum of mice at different ages.Results: APPswe/PS1dE9 mice exhibited declined memory beginning at 6 months of age, with cognitive capacity remarkably impaired at 12-months. Coincidently, amyloid deposits began to develop in transgenic mice brain at 6-months and increased with age. In addition, A beta 42 levels in brains of APPswe/PS1dE9 mice increased with age with no parallel increase in A beta 40. The concentration of serum A beta 42 declined from 4 to 6 months of age, but a similar age-dependent decrease was not observed for A beta 40.Conclusion: APPswe/PS1dE9 transgenic mice began to develop amyloid plaques at 6 months of age and exhibited a corresponding impairment of spatial learning capacity. Serum A beta 42 level decreased remarkably from 4 to 6 months, at which stage A beta 42 began to accumulate in the brain and deposit as plaques.
What problem does this paper attempt to address?